Spravato® vs. IV ketamine

Comparison table: nasal esketamine and IV ketamine

Two powerful tools, not the same treatment

For those living with treatment-resistant depression (TRD), the journey to finding relief can feel like an endless road of trial and error. When traditional antidepressants, psychotherapy, and other methods have failed to provide significant relief, a new frontier of treatment has emerged: ketamine and its FDA-approved derivative, Spravato® (esketamine). While both are powerful tools in the fight against severe depression, they are not the same.

This guide provides a side-by-side comparison of Spravato® and intravenous (IV) ketamine, helping you understand their core differences in administration, mechanism of action, safety protocols, cost, and the overall patient experience.

The science: a new mechanism of action

Traditional antidepressants, such as SSRIs and SNRIs, typically work by modulating neurotransmitters like serotonin and norepinephrine. While effective for many, they can take weeks or months to show results and don't work for everyone. Spravato® and IV ketamine offer an alternative by targeting the brain's glutamate system, a completely different pathway.

Glutamate is the most abundant excitatory neurotransmitter in the brain and plays a crucial role in regulating mood, memory, and cognitive function. In individuals with depression, the glutamate system can become imbalanced, leading to impaired neural connections.

Spravato® and IV ketamine work by blocking a specific type of glutamate receptor called the N-methyl-D-aspartate (NMDA) receptor. This inhibition leads to a surge in glutamate in the brain, which then activates other receptors (AMPA receptors). This process promotes rapid neuroplasticity, which is the brain's ability to reorganize itself by forming new synaptic connections. This "rewiring" helps the brain break free from the rigid, negative thought patterns associated with depression, leading to rapid symptom reduction, often within hours or days of the first session.

1. Administration: two delivery methods

Spravato® is a self-administered nasal spray. It is designed to be used by the patient under the direct, in-person supervision of a healthcare provider at a certified clinic. The process is non-invasive and straightforward. Patients typically receive their doses over a few minutes, with the healthcare provider present to guide them. This method is often preferred by those who are uncomfortable with needles or IV lines.

IV ketamine is an intravenous infusion, meaning it is delivered directly into the bloodstream through a needle and an IV line, usually in the arm. This process requires a healthcare professional to start and monitor the infusion. The treatment typically lasts about 40 minutes to an hour.

2. FDA approval, regulation, and safety

Spravato® is the only ketamine-based treatment to have received official FDA approval for treatment-resistant depression and for major depressive disorder with acute suicidal ideation or behavior. This approval comes with a strict safety protocol known as the Risk Evaluation and Mitigation Strategy (REMS) program. The REMS program mandates that Spravato® can only be administered in a certified healthcare setting, and patients must be closely monitored for at least two hours after each session.

IV ketamine is considered an "off-label" treatment for depression. While its use is widespread and many clinics offer it, it is not formally approved by the FDA for psychiatric conditions. This means its safety and usage are not subject to the same federal guidelines as Spravato®. Most reputable clinics follow their own protocols for patient safety, but there is no standardized, government-mandated system for all IV ketamine providers.

3. Cost and insurance coverage

Because it is an FDA-approved medication, Spravato® is typically covered by most major insurance providers, including many commercial plans, Medicare, and Medicaid. To get coverage, patients must undergo a prior authorization process, which usually requires documentation of a diagnosis of TRD (meaning at least two other antidepressant treatments have failed). Our team assists with this process, and patients are generally only responsible for their copay.

Since IV ketamine is an off-label treatment for depression, it is rarely covered by insurance. Patients often have to pay the full cost out of pocket. A full course of treatment can cost thousands of dollars.

4. Dosage and treatment schedule

Spravato® comes with clear, standardized guidelines. The typical schedule is an induction phase of twice a week for the first four weeks, then a maintenance phase of once a week for the next four weeks, and then once every one or two weeks thereafter, based on your response and your provider's recommendation.

The dosing for IV ketamine is more individualized, as there are no standardized protocols. The dosage (usually based on body weight) and frequency can vary widely from one clinic to another. This approach can be beneficial for some but may lead to a less predictable treatment journey.

5. What to expect: the patient experience

During the two-hour monitoring period after Spravato®, patients may experience side effects such as dizziness, nausea, a feeling of "floating" or being disconnected from themselves (dissociation), or a mild sense of euphoria. These sensations typically peak within the first hour and resolve during the observation period. Patients are advised to bring comfort items like a blanket, headphones, or a book. After the session, they may feel tired or groggy, and a responsible adult must drive them home.

Patients undergoing IV ketamine infusions often report a more intense dissociative experience during the 40 to 60 minute infusion, with sensations of unreality, altered perception, or a dream-like state. While some find this profound and therapeutic, others may find it unsettling. Patients are required to have a ride home, and it can be unsafe to drive or operate machinery for 24 hours.

Spravato® has an official, mandated REMS monitoring program, and any unusual experience by any patient is reported to a centralized database to help ensure future safety. Neither the DEA nor the FDA mandates a monitoring program with a centralized database for IV ketamine because it is off-label.

6. Patient eligibility and screening

Spravato® is not a first-line treatment for depression. Candidates must be adults (18+) with a diagnosis of treatment-resistant depression, meaning they have not had adequate relief from at least two different antidepressant medications taken at sufficient doses and duration. It is also approved for patients with major depressive disorder with acute suicidal thoughts. Contraindications include a history of certain cardiovascular conditions, uncontrolled high blood pressure, aneurysms, or a history of intracerebral hemorrhage.

While IV ketamine is also typically reserved for cases where traditional treatments have failed, the specific candidacy requirements vary by clinic. General contraindications are similar and may include uncontrolled hypertension, severe cardiovascular disease, a history of psychosis, or active substance abuse. The absence of a universal screening protocol makes it essential to choose a clinic with experienced medical staff who perform a comprehensive pre-treatment evaluation.

Conclusion

Both Spravato® and IV ketamine represent a significant advancement in the treatment of severe depression, offering hope where traditional methods have failed. However, their differences are substantial. Spravato® is defined by its FDA approval, standardized safety protocols, and insurance coverage, making it a more predictable and accessible option for many. IV ketamine, while a potent off-label treatment, offers a more individualized approach but comes with a lack of standardized oversight and is typically an out-of-pocket expense.

The decision of which treatment is right for you is a personal one that requires careful consideration and an in-depth discussion with a qualified mental health professional.

Frequently asked questions